Medications Requiring Complete Blood Count (CBC) Monitoring
Multiple medications require regular CBC monitoring to evaluate neutrophil, lymphocyte, and platelet counts due to their potential to cause hematologic abnormalities. 1
Tyrosine Kinase Inhibitors (TKIs)
- Imatinib requires CBC monitoring for potential neutropenia (ANC <1000/mm³), thrombocytopenia (platelets <50,000/mm³), and anemia 2
- Nilotinib requires CBC monitoring for neutropenia and thrombocytopenia, with dose adjustments when ANC <1000/mm³ or platelets <50,000/mm³ 2
- Dasatinib requires CBC monitoring for severe neutropenia (ANC <500/mm³) and thrombocytopenia (platelets <50,000/mm³) 3, 4
Management Algorithm for TKIs:
- Hold drug if ANC <1000/mm³ until ANC ≥1500/mm³, then resume at original dose 2
- If neutropenia recurs, hold drug until recovery and reduce dose 2
- Growth factors can be used in combination with TKIs for resistant neutropenia 2
Disease-Modifying Antirheumatic Drugs (DMARDs)
- Methotrexate requires CBC monitoring within 1-2 months of initiation and every 3-4 months thereafter 1
- Sulfasalazine requires CBC monitoring within 1-2 months of initiation and every 3-4 months thereafter 1
- Leflunomide requires CBC monitoring within 1-2 months of initiation and every 3-4 months thereafter 1
- Hydroxychloroquine requires annual CBC monitoring 1
Management Algorithm for DMARDs:
- Decrease or hold methotrexate or sulfasalazine if clinically relevant elevation in LFTs or decreased neutrophil/platelet count occurs 1
- For leflunomide, temporarily hold medication if ALT >3X the upper limit of normal 1
Immunosuppressive Medications
- Azathioprine requires weekly CBC monitoring during the first month, twice monthly for the second and third months, then monthly thereafter 5
- Mycophenolate mofetil requires regular CBC monitoring due to potential hematologic abnormalities 6
- TNF inhibitors require annual CBC monitoring 1
Special Considerations:
- Patients with TPMT deficiency receiving azathioprine are at higher risk for myelosuppression 5
- Drug interactions (e.g., allopurinol with azathioprine) can increase risk of cytopenia 5
Antibiotics and Other Medications
- Antimicrobial agents, particularly trimethoprim-sulfamethoxazole, can cause neutropenia 7
- Anti-tuberculosis medications including rifampicin and isoniazid can cause leukopenia 8
- NSAIDs require CBC monitoring every 6-12 months during chronic use 1
Chemotherapeutic Agents
- Cyclophosphamide and doxorubicin require CBC monitoring for neutropenia, with nadir typically occurring 10-14 days after administration 9, 10
- Radium-223 requires CBC monitoring with absolute neutrophil count ≥1.5 x 10^9/L, platelet count ≥100 x 10^9/L, and hemoglobin ≥10 g/dL prior to initial dose 11
Monitoring Recommendations
- For mild neutropenia (ANC 1.0-1.5 × 10^9/L), regular CBC monitoring is recommended 12, 13
- For severe neutropenia (ANC <0.5 × 10^9/L), implement antimicrobial prophylaxis and consider G-CSF therapy 12, 4
- Weekly CBC monitoring is recommended for the first 4-6 weeks for patients on treatments that may affect neutrophil counts 12, 13
Clinical Implications of Abnormal CBC Values
- Neutropenia increases infection risk, particularly when ANC falls below 500 cells/µL 12, 7
- Thrombocytopenia increases bleeding risk, requiring medication adjustments when platelets <50,000/mm³ 2
- Alterations in neutrophil, lymphocyte, and platelet counts can be prognostic indicators in various conditions 14